Tumor Microenvironment and Immunotherapy: The Whole Picture Is Better Than a Glimpse

Sarah E Church; Jérôme Galon

doi:10.1016/j.immuni.2015.10.004

Tumor Microenvironment and Immunotherapy: The Whole Picture Is Better Than a Glimpse

Immunity. 2015 Oct 20;43(4):631-3. doi: 10.1016/j.immuni.2015.10.004.

Authors

Sarah E Church¹, Jérôme Galon²

Affiliations

¹ INSERM, UMRS1138, Laboratory of Integrative Cancer Immunology, Paris, 75006, France; Université Paris Descartes, Paris 75006, France; Cordeliers Research Centre, Université Pierre et Marie Curie Paris 6, Paris 75006, France.
² INSERM, UMRS1138, Laboratory of Integrative Cancer Immunology, Paris, 75006, France; Université Paris Descartes, Paris 75006, France; Cordeliers Research Centre, Université Pierre et Marie Curie Paris 6, Paris 75006, France. Electronic address: [email protected].

PMID: 26488814
DOI: 10.1016/j.immuni.2015.10.004

Abstract

Predicting cancer patients' response to therapy is essential for curing disease and improving quality of life. Garraway and colleagues demonstrate that the frequency and number of neoantigens, non-synonymous mutations, and adaptive immune genes, but not the assessment of individual recurrent neoantigens or mutations, predicts patient responses to immunotherapy.

Publication types

Comment

MeSH terms

Antibodies, Monoclonal / pharmacology*
Antigens, Neoplasm / genetics*
Biomarkers, Pharmacological*
CTLA-4 Antigen / antagonists & inhibitors*
Female
Humans
Male
Melanoma / drug therapy*
Melanoma / genetics*
Skin Neoplasms / drug therapy*
Skin Neoplasms / genetics*

Substances

Antibodies, Monoclonal
Antigens, Neoplasm
Biomarkers, Pharmacological
CTLA-4 Antigen